Literature DB >> 33531697

Brolucizumab-foreseeable workflow in the current scenario.

Ashish Sharma1, Nilesh Kumar2, Nikulaa Parachuri2, Baruch D Kuppermann3, Francesco Bandello4, Carl D Regillo5, David Boyer6, Quan Dong Nguyen7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33531697      PMCID： PMC8169919          DOI： 10.1038/s41433-020-01324-w

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   4.456


× No keyword cloud information.
  5 in total

1.  Angiographic findings before and after the onset of brolucizumab-associated retinal vascular occlusion and intraocular inflammation.

Authors:  Sentaro Kusuhara; Kyung Woo Kim; Akiko Miki; Makoto Nakamura
Journal:  Am J Ophthalmol Case Rep       Date:  2022-04-14

2.  Intravitreal brolucizumab as treatment of early onset radiation retinopathy secondary to plaque brachytherapy for choroidal melanoma.

Authors:  Natacha C Villegas; Kapil Mishra; Nathan Steinle; Wu Liu; Beth Beadle; Prithvi Mruthyunjaya
Journal:  Am J Ophthalmol Case Rep       Date:  2022-05-14

3.  Swept-source optical coherence tomography angiography of retinal occlusive vasculitis following brolucizumab administration: a case report.

Authors:  Eun Kyoung Lee; Baek-Lok Oh; Chang Ki Yoon; Un Chul Park
Journal:  BMC Ophthalmol       Date:  2022-06-03       Impact factor: 2.086

4.  Intraocular inflammation secondary to intravitreal brolucizumab treated successfully with Sub-Tenon triamcinolone: A case report.

Authors:  Shree K Kurup; Tarek Tabbaa; Jose J Echegaray; Armando L Oliver
Journal:  Am J Ophthalmol Case Rep       Date:  2022-01-22

Review 5.  A CONSENSUS ON RISK MITIGATION FOR BROLUCIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Patient Selection, Evaluation, and Treatment.

Authors:  Frank G Holz; Tomohiro Iida; Ichiro Maruko; SriniVas R Sadda
Journal:  Retina       Date:  2022-06-13       Impact factor: 3.975
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.